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HIV infection and AIDS comprise one of the main public 
health challenges facing South Africa (SA). In response to the 
epidemic, the National Department of Health (NDoH) initiated 
the Comprehensive Care, Management and Treatment of HIV and 
AIDS (CCMT) programme in 2004. In 2007, the NDoH outlined 
its plans to extend the HIV & AIDS and STI Strategic Plan for 
South Africa 2007 - 2011 (NSP).[1] The primary aim of the NSP 
was to reduce the prevalence of HIV by 50% and to expand access 
to treatment, care and support to 80% of people who need it by 
2011 and beyond.[2] In August 2011, the NDoH released the new 
NSP for the period 2012 - 2016.[3] The key goals set by the NSP for 
2012 - 2016 were to reduce the rate of new HIV infections and HIV-
associated maternal mortality by 50% as well as reducing new HIV 
infections in children by 90%.[3]
In support of this programme, the National Health Laboratory 
Service (NHLS) provided 3.9 million CD4 tests during 2013/14, 
through a network of 61 laboratories across SA.[4] Analysis of 
CD4 laboratory data provides important information on the 
CCMT programme, reported monthly to the NDoH, including 
the median CD4 counts for various age groups, with the 
related test request volumes across districts. Currently, however, 
information from sample request forms does not include 
information to identify the proportion of patients accessing care 
for the first time v. those who are already enrolled into care and 
being followed up, or alternatively are in wellness programmes 
waiting to qualify for treatment. This information is critical to 
determine the impact of HIV programmes on patient initiation, 
and to assist in management of patient monitoring and access 
to care.
Objectives
The objectives of this study were threefold. Firstly, the usefulness of 
introducing a ‘two-tick’ system on an improved test request form, 
linked to CD4 testing, was explored for linking the CD4 count to 
patient CCMT programme status. This made it possible to identify 
treatment-naive patients (first-time CD4 counts) from those in 
staging and already enrolled for antiretroviral treatment (ART). 
Secondly, the proportions of patients in the pre-ART and ART 
programme status categories (as well as within specific age groups) 
as a percentage of total CD4 samples received could be analysed to 
assess overall numbers of specific patient groups who are accessing 
and/or eligible for treatment (or not) in a given healthcare facility. 
Thirdly, the median CD4 counts within groups characterised by this 
two-tick system could be used to provide information about overall 
patient wellness according to CCMT status provided within defined 
age groups.
Methods
A cross-sectional study was designed to evaluate CCMT data 
collection enabled by introduction of a new data collection instrument 
(a redesigned CCMT request form) that was introduced at three HIV 
clinics in Ekurhuleni Metropolitan Municipality, Gauteng Province, 
SA (the study sites were Tambo Memorial, Far East Rand and 
Tembisa). A MaCorr sample size of 1 200 CD4 samples was calculated 
for the study, with 500 collections planned for the Tambo Memorial 
study site and 350 each for the Far East Rand and Tembisa. Samples 
from patients <18 years of age were excluded.
To assess the success of the implementation, CD4 data were extracted 
from the NHLS Corporate Data Warehouse (CDW) for 2 months (June 
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and July 2012) prior to implementation of the 
new form, and data were analysed using Excel 
and Intercooled Stata 11. This analysis enabled 
an assessment of baseline CCMT data captured 
before introduction of the new form. The new 
request form was designed to incorporate two 
additional sets of tick blocks that were added 
onto the existing NHLS request form, in close 
proximity to the CD4 test request tick box. 
By ticking a tick block linked to the CD4 
test request, a healthcare worker was able to 
provide specific information about the patient’s 
related CCMT programme status. Available 
options were ‘first-ever CD4’ count, ‘CD4 taken 
previously, not yet in ART care’ and ‘in ART 
care’. New data fields were established on the 
NHLS Laboratory Information System (LIS) 
to facilitate the data capture of the three new 
CCMT status parameters. CD4/CCMT data 
were categorised to identify forms on which 
the required information was incorrectly filled 
out or not filled out at all. Data capture rates 
before (number of sample data entries with 
any relevant linked CCMT information before 
implementation) and after implementation of 
the new data collection form were calculated. 
Only LIS/CDW CD4 data entries that were 
linked to the new CCMT test request form 
(identified with a custom barcode sequence) 
were included in the ‘post-implementation’ 
analysis data set.
After collection of LIS data through CDW, 
the post-implementation CD4 and CCMT 
data were organised according to CCMT 
programme status. Median CD4 counts were 
calculated for each group and the proportion 
of samples established according to gender, 
specified antenatal survey age groups[5] and 
predefined CD4 range distributions. The latter 
was based on previous and current treatment 
thresholds to indicate the level of wellness/
immune deficiency per subgroup analysed.[6]
Results
During the study period, redesigned CCMT 
request forms were received with 1 266 CD4 
samples from the three participating study 
sites, reaching 99% of the target sample 
size. Seventy-six CD4 sample results (6.0%) 
from children aged <18 years were excluded, 
leaving 1 190 CD4 data entries for final 
analysis (94.0%). The contribution analy ses of 
the three clinics showed that 46.8% (n=557) 
of CD4 sample requests were received from 
the Tambo Memorial study site, 31.8% 
(n=378) from Tembisa and the remaining 
21.4% (n=255) from the Far East Rand.
CCMT programme status data were not 
captured on 186/1 190 (15.6%) of new request 
forms received. In 165/186 (88.7%), no infor-
mation/programme status was captured on 
the LIS. In 17/186 instances (9.1%), the 
CCMT information was incorrectly captured 
by the LIS data clerk and an invalid option 
was provided in the programme status field. 
These were categorised as ‘programme 
status not relevant to study’, and comprised 
entries such as ‘3TC’ (n=4), ‘D4T’ (n=1), 
‘adverse effect’ (n=4), ‘non-adherence’ (n=1), 
‘virological failure’ (n=1) and ‘toxicity’ (n=6).
In 4/186 instances (2.2%), the healthcare 
worker did not check any of the new request 
form tick blocks; these were identified and 
entered onto the NHLS LIS by the NHLS 
data clerks as ‘no details supplied’.
Table 1 outlines the impact of the new 
form and related new three-option tick-
block system, compared with the pre-
implementation proportion of existing request 
forms with CCMT data captured. Despite the 
fact that 15.6% of new forms were incorrectly 
or not filled out, the linked tick-block system 
on the new CCMT form enabled a >300% 
increase in the number of forms received with 
relevant useful patient CCMT data.
Fig. 1 outlines analyses performed on 
the remaining data (n=1 004), characterised 
Table 1. CCMT programme status data capture rates before and after the study
Category
Samples with 
CCMT programme 
status, n
Samples without 
CCMT programme 
status, n Total, N
% of samples with 
CCMT programme 
status
Pre-study 873 2 230 3 103 28.1
Study 1 004 186 1 190 84.4
Fig. 1. CD4 test range, age and gender distribution for each CD4 CCMT programme status.
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according to CCMT status. The latter included: (i) ‘pre-ART’, which 
was further defined as ‘first-ever CD4’ or ‘CD4 taken previously, not 
yet in care’; or (ii) ‘ART’. Data were further categorised by specific 
age categories as described above, as well as by CD4 count threshold, 
including <50, 100, 200, 350 and <500 cells/μL categories.
Patient gender information was captured for 99.8% of CD4 
samples, 58.3% from female patients (n=585) and 41.6% (n=417) 
from males (ratio ~3:2). A similar gender proportion was noted 
across all CCMT categories (Fig. 1), with the exception of the group 
‘CD4 taken previously, but not yet in care’, where the ratio of female 
to male patients more than doubled, increasing to ~7:3. The majority 
of CD4 samples received were from patients aged between 30 and 44 
years (60.1%), with 13.5% and 26.4% of samples from patients aged 
18 - 29 years and >44 years, respectively. These proportions were 
similar across all CCMT groups.
Of the CD4 samples, 38.1% (n=383) were identified as ‘pre-
ART’, ‘first-ever CD4’ CCMT programme status comprised 30.8% 
(n=309), and ‘CD4 taken previously, not yet in ART care’ comprised 
7.4% (n=74). A summary of age and CD4 range distribution is 
shown in Fig. 1. In the treatment-naive patient group (‘first-ever 
CD4’), 89.3% of patients were eligible for treatment at the current 
2015 treatment guideline threshold of 500 CD4 cells/µL.[6] The 
majority of the patients in this group had a median CD4 count of 
150 cells/µL. Overall, 78.6% overall had a CD4 count <350 cells/µL; 
59.2% of this group presented with a CD4 count <200 cells/µL, while 
40.5% were at risk for opportunistic cryptococcal infection, having 
CD4 counts <100 cells/µL. The group of patients awaiting enrolment 
into ART care (‘CD4 taken previously, not yet in ART care’), had 
a slightly lower proportion of patients with very low CD4 counts 
(17.6%), with a very high proportion eligible for ART at the current 
guideline threshold (78.4%).
Patients identified as ‘in ART care’ comprised 61.9% of CD4 test 
requests overall (n=621). Although a smaller proportion of patients 
could be categorised as markedly immunosuppressed (6.4% had a 
CD4 count of <100 cells/µL and 23.2% a count of <200 cells/µL), 
similar results for immunosuppressed patients awaiting enrolment 
into care were noted in this group. This was confirmed by the median 
CD4 count of 347 cells/µL, which was only slightly higher than the 
median of 324 cells/µL noted in the ‘awaiting enrolment’ group.
Discussion
This study was designed to link a CD4 count to patient programme 
status by the simple addition of two tick boxes on an existing 
sample request form. Healthcare workers were prompted to provide 
additional relevant CCMT information, with minimal interruption to 
routine healthcare workflow. Compliance among healthcare workers 
providing this programme information increased from 28.1% to 
84.4%. It is clear that this simple modification to the request form was 
successful for three reasons. Firstly, the layout and placement of the 
relevant tick boxes meant that the healthcare worker was no longer 
required to search for the programme status fields located elsewhere 
on the (existing) request form, and the request for additional 
information was not ambiguous. Secondly, the direct linking and 
proximal placement of the CD4 test request to the tick block for 
programme status vastly improved data collection of relevant patient 
programme status. Thirdly, simplifying the data collection to two 
choices related to the timing of the CD4 test request and whether 
the patient was on treatment or not further encouraged compliance 
among attending healthcare personnel.
The successful use of this pilot request form, although limited to 
just 2 months of CCMT across three clinics in Ekurhuleni in Gauteng, 
had positive outcomes with important implications for collection and 
collation of national programme CCMT data. The simple directive 
of providing information about whether a CD4 count is ‘first-ever’ 
v. ‘done previously’ can be used to assess how many new patients 
are accessing HIV counselling and testing (HCT) and/or care and to 
ascertain the success of local programmes and associated proportions 
of patients who need fast-tracking and linkage to care (an aspect that 
is currently lacking in national reports). This information can be 
used to ensure that first-time HIV-positive patients start treatment 
as early as possible (according to threshold guidelines) to prevent late 
presentation, which is associated with opportunistic infections and 
hospitalisation.
In this study, a median CD4 count of 150 cells/µL was noted in 
the group of patients having their first-ever CD4 count, indicating 
a markedly immunosuppressed group in need of urgent treatment 
intervention. Such low median presentation CD4 counts, similar to 
counts described locally[9] and elsewhere in Africa,[7] increase the 
likelihood of disease progression to AIDS, opportunistic infection and 
death if patients are not initiated on ART.[8] According to the World 
Health Organization immunological classification for established 
HIV infection,[8] this group has twice the risk of death or virological 
failure and may also be more likely to have opportunistic infections 
and other HIV-related conditions complicating presentation. 
Enabling these patients to be identified by linking programme status 
to CD4 results may allow for laboratory monitoring systems to be 
implemented to facilitate preselecting them for fast-tracking onto 
ART. There is an impression that the patients presenting for the first 
time are generally less ill than those seen at the start of the SA CCMT 
programme (monthly NHLS CDW CCMT reports, unpublished). 
However, lack of information and identification of patients with ‘first-
ever CD4s’ combined with at least a two-thirds majority enrolled 
onto treatment skews the overall median CD4 counts of this group, 
and gives the impression that CD4 counts of patients presenting for 
first-time HIV/CD4 testing have improved during the course of the 
CCMT programme. The data presented here show that people are 
still waiting until they feel ill before they present for HCT, with a 
median CD4 count of <200 cells/µL not vastly different from counts 
reported at the start of the CCMT programme.[9]
Furthermore, although it is commendable that a significant 
proportion of patients were already enrolled and ‘in ART care’ 
(62.1%), it could not be ascertained from this study how long these 
patients had been enrolled in care. It is still worrying that overall lack 
of wellness and relative immunosuppression despite treatment still 
prevails in this group (median CD4 count just 347 cells/μL).
This study showed that mainly women presented for care. More 
than one-third had presented for HCT but were yet to start ART, and 
close to 90% of new patients were eligible for treatment. Of interest 
was the high proportion of females in the ‘not yet enrolled in ART 
care’ group. Reasons for the latter were not obvious.
The study confirmed that a simple modification to the existing 
request form can have a dramatic impact on how, and what, 
programmatic information is collected in relation to CD4 test 
requests. The challenge, however, is how this type of data collection 
tool can be scaled up to include other necessary related programme 
information (e.g. HIV viral load and screening for related HIV 
opportunistic infections/associated TB diagnostics) without making 
existing request forms too cumbersome with additional tick blocks. 
Unique patient identifiers are currently not used in our local 
healthcare databases despite use of unique identifiers, e.g. SA ID 
numbers, elsewhere in local government programmes to accurately 
collect and collate legitimate participant data (e.g. citizens who collect 
welfare grants are required to provide their SA ID numbers). [10] 
Adopting the use of such master patient identifiers (MPIs) can have 
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an immediate and dramatic impact on how local healthcare data 
are managed. Valuable information can be extracted immediately, 
without either necessitating modifications to request forms or 
developing indirect systems utilising less optimal methods that 
attempt to link and match variable patient identifiers to relevant 
diagnostic data, e.g. probabilistic matching in existing databases 
(personal communication, Dr Sergio Carmona, NHLS). Examples 
of where use of MPIs would significantly improve patient outcome 
include being able to track patients longitudinally by capture date and 
identify patients’ ‘first-ever’ CD4 through to ART initiation (linked to 
‘first-ever’ HIV viral load test requests), while additionally providing 
provincial and district alerts that could assist HIV programme 
co-ordinators in identifying patients who require immediate care 
(e.g. those with asymptomatic cryptococcal antigenaemia, where 
early intervention with fluconazole therapy can prevent progression 
to meningitis, potentially saving a life).
Conclusion
The challenges related to tracking patients from the point of entry 
at the time of HCT (denoted here as ‘first-ever CD4’) to enrolment 
onto a treatment programme (denoted here as ‘ART initiation’) 
are well described.[11-15] Current specimen-based laboratory data 
systems are unable to provide this information because of absence 
of national patient identifiers to track individual patients as they 
progress through HCT to ART. The collection of programme data for 
routine CD4 testing on a data collection instrument using a two-tick 
system is proposed. This system demonstrated a significant uptake in 
the provision of data. The poor immune status of patients receiving 
their first-ever CD4 count identified by the study was a cause for 
concern, highlighting the challenges related to late presentation and 
misinterpretation of bundled CD4 data (no distinction between 
pre-ART v. ART). The potential of the data collection tool to assess 
the immunological status of patients presenting for pre-ART care 
across SA, once implemented, could supplement existing data 
collection systems that are mainly focused on ART.[16] The value of 
integrating programme data collection with routine CD4 testing 
through a national request form lies in the ease of implementation 
at health facilities. The outcomes of this study indicate that it would 
be sustainable to implement the collection of programme data for 
routine CD4 testing across SA to improve management of HIV 
patients, either on or awaiting treatment.
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